🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in India / NCT06853834
Recruiting Not applicable

Comparative Diagnostic Yield of Endobronchial Cryo Biopsy vs Forceps Biopsy in Patients With Suspected Sarcoidosis

NCT06853834 · tracked via the Priya Life Science India tracker
Sponsor
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Phase
Not applicable
Started
2024-01-01
Last updated
2025-03-03

Condition(s) studied

Sarcoidosis LungPulmonary Sarcoidosis

Investigational drug(s) / intervention(s)

Cryobiopsy with liquid nitrogenEndobronchial Forceps Biopsy

Cryobiopsy with liquid nitrogen: Forceps vs Cryo Endobronchial Biopsy

Endobronchial Forceps Biopsy: Comparision of forceps and cryo endobronchial biopsy

Study summary

Sarcoidosis is a multi-systemic granulomatous disease of unknown cause that is characterized by the formation of non-caseous epithelioid cell granulomas. Sarcoidosis involves the respiratory system in \> 90% of cases, usually the hilar and mediastinal nodes, and, less frequently, the lung tissue. Airway involvement, as judged by clinical features, physiologic testing, imaging techniques, bronchoscopy, and airway mucosal biopsy, has been observed in nearly two-thirds of patients with sarcoidosis. Although sarcoidosis involving thoracic lymph nodes and pulmonary parenchyma is familiar to most clinicians, airway involvement is often overlooked. The frequency of airway involvement increases as the parenchymal disease progresses, and\\airway involvement is associated with increased morbidity, respiratory symptoms, and mortality. The initial airway abnormality is the inflammation manifested by mucosal edema, erythema, and the formation of granulomas. As the airway disease progresses, the mucosa may demonstrate granularity, nodularity, cobble stoning, and friability. Sarcoid granulomas tend to develop along the bronchovascular bundle or in the vicinity of the airways. Overall quality of the endobronchial biopsy (EBB) will depend on the method by which it is obtained and cryo-EBB will most likely to provide better tissue for the diagnosis in comparison to forceps biopsy which has smaller sample as well as crush artifacts. Therefore, it is hypothesized that cryo-EBB will be better than forceps EBB and combined together it will increase the overall diagnostic yield of the sarcoidosis when combined with lymph node sampling by endobronchial ultrasound guided trans-bronchial needle aspiration (EBUS-TBNA).

1. Primary objective: To compare the diagnostic yield of cryo-EBB with forceps biopsy in patients undergoing routine EBUS-TBNA for suspected sarcoidosis.
2. Secondary Objective: To evaluate the overall diagnostic yield of combined endobronchial biopsy and EBUS-TBNA in patients undergoing routine EBUS-TBNA for suspected sarcoidosis.

The relevance and the expected outcome of the proposed study

1. The study will provide insight to obtain an endobronchial biopsy either with cryo probe or forceps
2. The study will also provide information regarding overall increase in diagnostic yield if any when the endobronchial biopsies are combined with EBUS-TBNA.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: All patients of suspected pulmonary sarcoidosis scheduled for routine EBUS-TBNA Exclusion Criteria: 1. Patient age less than 18 years 2. Patients with co-morbid conditions like Diabetes mellitus, renal failure, chronic liver disease or any other chronic disease. 3. Patients already on treatment with steroids or h/o steroids intake in last three months or on disease modifying and immunosuppressive drugs. 4. Final Diagnosis other than sarcoidosis

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow Uttar Pradesh Recruiting

More Sanjay Gandhi Postgraduate Institute of Medical Sciences trials in India

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06853834 on ClinicalTrials.gov ↗ ← All trials in India